Immunovant (IMVT) Amortization of Deferred Charges (2020 - 2026)
Immunovant (IMVT) posted Amortization of Deferred Charges of $26000.0 for Q1 2026, up 4.0% on a QoQ basis from $25000.0 in Q4 2025, and up 18.18% year-over-year from $22000.0 in Q1 2025.
Immunovant (IMVT) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Immunovant's Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $26000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 18.18% year-over-year to $26000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99000.0 (down 25.56% YoY) and the FY2026 annual result came in at $99000.0, down 25.56% from the prior year.
- Amortization of Deferred Charges was $26000.0 for Q1 2026 at Immunovant, up from $25000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $295000.0 in Q4 2023 and bottomed at $22000.0 in Q3 2024.
- A 5-year average of $162823.5 and a median of $252000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges rose 25.57% — and 2024, when it plunged 92.49%.
- Immunovant's Amortization of Deferred Charges stood at $284000.0 in 2022, then climbed by 3.87% to $295000.0 in 2023, then sank by 92.2% to $23000.0 in 2024, then rose by 8.7% to $25000.0 in 2025, then grew by 4.0% to $26000.0 in 2026.
- Business Quant data shows IMVT's Amortization of Deferred Charges at $26000.0 in Q1 2026, $25000.0 in Q4 2025, and $24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn |
| 10 | Immunovant | 7.33 Bn | 6.43 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26,000.00 |
| Mar 31, 2026 | 26,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2023 | 295,000.00 |